Integra LifeSciences Holdings Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mojdeh Poul
- Full Time Employees
- 4,396
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1100 Campus Road Princeton NJ United States of America 08540
- IPO Date
- Aug 16, 1995
- CIK
- 0000917520
- Website
- integralife.com
- Similar Companies
- Business
- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global medical technology company founded in 1989 and headquartered in Princeton, New Jersey, develops, manufactures and markets surgical implants, instruments and regenerative technologies for neurosurgery, neurocritical care, extremity reconstruction, otolaryngology, wound care and general surgery; operates in two segments, Codman Specialty Surgical and Tissue Technologies; offers neurosurgery products including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, cranial stabilization equipment, surgical headlamps and instrumentation; provides over 40,000 instrument patterns, surgical and lighting products for hospitals, surgery centers, dental, podiatry and veterinary offices; supplies regenerative products for acute and chronic wounds such as burns and diabetic foot ulcers, along with surgical tissue repair solutions for hernia, tendon, peripheral nerve repair and protection, skin and bone grafts; delivers ear, nose and throat solutions encompassing instrumentation, balloon technologies for sinus and eustachian tube dilation, surgical navigation systems and the MicroFrance line; and sells directly through sales forces and distribution channels to hospitals, integrated health networks, group purchasing organizations and clinicians in the United States, Europe, Asia Pacific and internationally. The company recently completed its acquisition of Acclarent, Inc. from Johnson & Johnson MedTech in 2024 for $275 million plus up to $5 million in regulatory milestones, enhancing its ear, nose and throat portfolio with leading balloon sinuplasty and eustachian tube dilation technologies integrated into the Codman Specialty Surgical division; integrated the 2022 Surgical Innovation Associates acquisition, adding the DuraSorb resorbable synthetic matrix for plastic and reconstructive surgery including implant-based breast reconstruction; and continues to report organic revenue growth, with 7.1% in Q3 2025 amid focus on neurosurgical, ENT and regenerative product expansions.
IART vs. MASI: Which Stock Should Value Investors Buy Now?
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
Integra LifeSciences Holdings Corporation (IART) Hit a 52 Week High, Can the Run Continue?
4 High-Growth GARP Stocks With Attractive PEG Ratios for 2026
Integra LifeSciences (IART) is a Top-Ranked Value Stock: Should You Buy?
IART or MASI: Which Is the Better Value Stock Right Now?
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears
Integra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra (IART) Upgraded to Buy: What Does It Mean for the Stock?
Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra LifeSciences Reports First Quarter 2026 Financial Results
Integra LifeSciences Announces Leadership Transition
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Is This the Right Time to Hold IART Stock in Your Portfolio?